Evusheld significantly prevented COVID-19 disease progression or death in TACKLE Phase III treatment trial

Results published in The Lancet Respiratory Medicine support benefits of Evusheld in the outpatient treatment of mild-to-moderate COVID-19 Detailed results from the TACKLE Phase III outpatient treatment trial showed AstraZeneca‚Äôs Evusheld (tixagevimab and cilgavimab, formerly AZD7442) provided clinically and statistically Read More …